Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context

Nkuba-Ndaye, Antoine; Mukadi-Bamuleka, Daniel; Bulabula-Penge, Junior; Thaurignac, Guillaume; Edidi-Atani, François; Mambu-Mbika, Fabrice; Danga-Yema, Bernice; Matondo-Kuamfumu, Meris; Kinganda-Lusamaki, Eddy; Bisento, Nella; Lumembe-Numbi, Raphaël; Kabamba-Lungenyi, Gabriel; Kitsa-Mutsumbirwa, Divine; Kambale-Sivihwa, Nelson; Boillot, François; Delaporte, Éric; Mbala-Kingebeni, Placide; Ayouba, Ahidjo; Peeters, Martine; Ahuka‐Mundeke, Steve

doi:10.1093/infdis/jiac057

Cited by 9 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this integrated view is still likely to be incomplete, as some cases and contacts could only be identified as probable, suggesting that additional EVD cases might not have been fully documented, which was similar to observations from the tenth EVD outbreak in Nord Kivu Province, Democratic Republic of the Congo. 21 In our epidemiological case investigations, we reported evidence that the 2020 Équateur Province EBOV outbreak started in the Mbandaka health zone and originated from an individual who frequently consumed bat meat and, using genetic data, we demonstrated that the EBOV sequence from the index case represented a new Ebola virus variant. Using additional genetic evidence, we demonstrated that a second EBOV variant re-emerged from an EVD survivor of the previous 2018 Équateur outbreak during the same timeframe.…”

Section: Discussionmentioning

confidence: 78%

2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation

Kinganda-Lusamaki,

Whitmer,

Lokilo-Lofiko

et al. 2024

The Lancet Microbe

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 78%

2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation

Kinganda-Lusamaki,

Whitmer,

Lokilo-Lofiko

et al. 2024

The Lancet Microbe

Self Cite

View full text Add to dashboard Cite

“…Seropositivity was very high when looking at serology in people who had past infections e.g. (36) compared to the general population e.g. (37).…”

Section: Discussionmentioning

confidence: 99%

Ebola Virus Disease mathematical models and epidemiological parameters: a systematic review and meta-analysis

Nash,

Bhatia,

Morgenstern

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Ebola Virus Disease (EVD) poses a recurring risk to human health. Modelling can provide key insights informing epidemic response, hence synthesising current evidence about EVD epidemiology and models is critical to prepare for future outbreaks. Methods: We conducted a systematic review (PROSPERO CRD42023393345) and meta-analysis of EVD transmission models and parameters characterising EVD transmission, evolution, natural history, severity, risk factors and seroprevalence published prior to 7th July 2023 from PubMed and Web of Science. Two people screened each abstract and full text. Papers were extracted using a bespoke Access database, 10% were double extracted. Meta-analyses were conducted to synthesise information where possible. Findings: We extracted 1,280 parameters and 295 models from 522 papers. Basic reproduction number estimates were highly variable (central estimates between 0.1 and 12.0 for high quality assessment scores), as were effective reproduction numbers, likely reflecting spatiotemporal variability in interventions. Pooled random effect estimates were 15.4 days (95% Confidence Interval (CI) 13.2-17.5) for the serial interval, 8.5 (95% CI 7.7-9.2) for the incubation period, 9.3 (95% CI 8.5-10.1) for the symptom-onset-to-death delay and 13.0 (95% CI 10.4-15.7) for symptom-onset-to-recovery. Common effect estimates were similar albeit with narrower CIs. Case fatality ratio estimates were generally high but highly variable (from 0 to 100%), which could reflect heterogeneity in underlying risk factors such as age and caring responsibilities. Interpretation: While a significant body of literature exists on EVD models and epidemiological parameter estimates, many of these studies focus on the West African Ebola epidemic and are primarily associated with Zaire Ebola virus. This leaves a critical gap in our knowledge regarding other Ebola virus species and outbreak contexts. Funding: UKRI, NIHR, Academy of Medical Sciences, Wellcome, UK Department for Business, Energy, and Industrial Strategy, BHF, Diabetes UK, Schmidt Foundation, Community Jameel, Royal Society, and Imperial College London.

show abstract

“…While the EBOV seroprevalence in Boende after the previous epidemic of 2014 was high (28.1%) among healthy HCP never reporting an infection [24], the seroprevalence estimate was much lower in another study conducted in the same area (7%) [22]. A serosurvey conducted on blood samples collected from clinically suspected EVD cases that were sent home after testing negative in two consecutive EBOV RT-PCR during the tenth EBOV outbreak in DRC Ituri, Nord Kivu and Sud Kivu provinces, 2018-2020), reported an EBOV antigen seroreactivity of 2.3% [25] (Table 1). However, despite many studies assessing the GP-EBOV antigen seroreactivity in different populations and different locations/countries, the interpretation of this seroprevalence data is challenging given the variation of the assays employed and diversity of cutoff algorithms used [8,12,18,[26][27][28].…”

Section: Introductionmentioning

confidence: 89%

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Zola Matuvanga,

Mariën,

Larivière

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7–2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0–1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5–10.9) samples using FANG ELISA. Conclusion In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.

show abstract

Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context

Cited by 9 publications

References 13 publications

2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation

2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation

Ebola Virus Disease mathematical models and epidemiological parameters: a systematic review and meta-analysis

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Contact Info

Product

Resources

About